Search clinical trials for: ABT-874

Total 4759 results

AbbVie (prior sponsor, Abbott)
Paragon Biomedical

Completed

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection

Chronic Hepatitis C Infection
AbbVie

Completed

A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis

Erosive Hand Osteoarthritis
Abbott

Completed

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects

Healthy

United States
AbbVie

Completed

A Phase 1 Study of ABT-869 in Subjects With Solid Tumors

Solid Tumor
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869

Advanced Solid Tumors
AbbVie (prior sponsor, Abbott)

Completed

Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Completed

A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid

Healthy

United States
Abbott

Completed

A Safety and Tolerability Study of ABT-126 in Elderly

Alzheimer's Disease

United States
Abbott

Completed

Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation

Hepatitis C

United States
AbbVie (prior sponsor, Abbott)

Completed

An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types

Advanced Solid Tumors

Australia
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection

Chronic Hepatitis C | Hepatitis C Virus | HCV
AbbVie (prior sponsor, Abbott)
Paragon Biomedical

Completed

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

United States
Linnaeus University
Kronoberg County Council; Capio Group

Completed

PCBH With the Addition of Self-help CBT

Quality of Life | Stress | Insomnia | Psychological Distress | Depression, Anxiety | Activities, Daily Living

Sweden
Global Alliance for TB Drug Development

Completed

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis Infection

United States
University of California, San Francisco
National Institute of Mental Health (NIMH)

Completed

An Adaptive Intervention for Depression Among Latinos Living With HIV (Latino-SMART)

Depression

United States
AbbVie

Completed

Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects

HCV Infection
AbbVie (prior sponsor, Abbott)

Completed

Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Completed

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness

Sleep Disorder

United States
Abbott

Terminated

An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia

Schizophrenia

United States, Argentina, Mexico
Abbott
Abbott Japan Co.,Ltd

Completed

A Study of Single Doses of ABT-072 in Japanese Healthy Male Adults

Hepatitis C

Japan
Abbott
Abbott Japan Co.,Ltd

Completed

A Study of Single Dose of ABT-333 in Healthy Male Adults

HCV Infections

Japan
Abbott

Completed

Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072

Hepatitis C

United States
Abbott

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet

HCV Infection

United States
AbbVie (prior sponsor, Abbott)

Terminated

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Poland, Russian Federation, South Africa, Ukraine, United Kingdom
AbbVie

Terminated

Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

Schizophrenia

United States, Russian Federation, United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Fallopian Tube | Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian

Netherlands
AbbVie

Terminated

[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Australia
AbbVie

Completed

Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects

Relative Bioavailability

United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

Hepatitis C Virus Infection

United States
AbbVie (prior sponsor, Abbott)

Completed

A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
Abbott

Terminated

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

Alzheimer's Disease

United States
Abbott

Terminated

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

Alzheimer's Disease

United States
AbbVie

Completed

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

Hepatitis C

United States, Australia, Belgium, Canada, Germany, New Zealand, Puerto Rico, United Kingdom
AbbVie

Completed

A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection (ENDURANCE-3)

Chronic Hepatitis C | Hepatitis C Virus | Genotype 3 Hepatitis C Virus
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)

Hepatitis C Virus Infection | Chronic Hepatitis C | Compensated Cirrhosis
Kafrelsheikh University

Completed

Ridge Augmentation With Simultaneous Implant Placement Using Bone Blocks With Autogenous Tooth Graft

Implant | Ridge Augmentation | Autogenous Tooth Graft

Egypt
AbbVie

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (PEARL-IV)

Chronic Hepatitis C Infection
Shenzhen TargetRx, Inc.
Institute of Hematology & Blood Diseases Hospital, China

Recruiting

TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Non Hodgkin Lymphoma | Hematologic Malignancy | Acute Lymphoblastic Leukemia, Adult

China
AbbVie

Terminated

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Alzheimer's Disease

United States
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

United States, Canada, France, Singapore, Taiwan
Chinook Therapeutics, Inc.

Recruiting

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy (ASSIST)

Immunoglobulin A Nephropathy | IgA Nephropathy

Spain, Australia, United States
US Department of Veterans Affairs

Completed

Behavioral Treatments for Chronic Pain

Intractable Pain

United States
AbbVie

Completed

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

Hepatitis C Virus (HCV)

United States, Bulgaria, Canada, France, Germany, Poland, Puerto Rico, Russian Federation, Spain, United Kingdom
AbbVie

No longer available

Expanded Access to ABT-414

Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis
M.D. Anderson Cancer Center

Completed

Study of ABT-751 in Patients With Refractory Hematologic Malignancies

Hematological Malignancies

United States
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

United States, Canada, Singapore, Taiwan
Abbott

Terminated

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Completed

Exploratory Positron Emission Tomography (PET) Study to Evaluate the Effects of ABT-614 on [11C]-(+)-PHNO Binding Potential to D3 Receptors in the Brain

Healthy Volunteers

Canada

3

Subscribe